公开(公告)号：US20240277841A2

公开(公告)日：2024-08-22

申请号：US18256916

申请日：2021-12-10

申请人： Purdue Research Foundation

发明人： Xiaoping BAO ,  Qing DENG ,  Yun CHANG ,  Ramizah MOHD SABRI

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/435 ,  C12N5/0787 ,  C12N15/85

CPC分类号： A61K39/461 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/43522 ,  C12N5/0642 ,  C12N15/85 ,  C12N2501/125 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/385 ,  C12N2506/03 ,  C12N2800/107

摘要： The present disclosure relates to a stage-specific process for manufacturing a population of neutrophils, such as chimeric antigen receptor-expressing (CAR-expressing) neutrophils (e.g., T cells and natural killer (NK) cells), from human pluripotent stem cells (hPSCs) using defined media and related compositions, kits, and methods of use (e.g., targeted cancer immunotherapy). Stage-specific processes for generating neutrophils and chimeric antigen receptor (CAR) neutrophils from human pluripotent stem cells (hPSCs) using chemically defined, feeder-free platforms and stage-specific morphogens; cell lines; pharmaceutical compositions; a method of treating cancer; and a kit are within the scopes of this disclosure.

公开(公告)号：US20240228977A1

公开(公告)日：2024-07-11

申请号：US18449100

申请日：2023-08-14

申请人： FUJIFILM Cellular Dynamics, Inc.

发明人： Amanda MACK

IPC分类号： C12N5/074 ,  C12N15/85

CPC分类号： C12N5/0696 ,  C12N15/85 ,  C12N2500/98 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2506/11 ,  C12N2510/00

摘要： Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from peripheral blood cells, such as human blood progenitor cells, using episomal reprogramming and feeder-free or xeno-free conditions. In certain embodiments, the invention provides novel methods for improving overall reprogramming efficiency with low number of blood progenitor cells.

公开(公告)号：US20240024473A1

公开(公告)日：2024-01-25

申请号：US18256916

申请日：2021-12-10

申请人： Purdue Research Foundation

发明人： Xiaoping BAO ,  Qing DENG ,  Yun CHANG ,  Ramizah MOHD SABRI

IPC分类号： A61K39/00 ,  C12N5/0787 ,  C12N15/85 ,  A61P35/00 ,  C07K14/435

CPC分类号： A61K39/461 ,  C12N5/0642 ,  C12N15/85 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/43522 ,  C12N2800/107 ,  C12N2506/03 ,  C12N2501/22 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/125 ,  C12N2501/26 ,  C12N2501/385 ,  C12N2501/2303 ,  C12N2501/2306

摘要： The present disclosure relates to a stage-specific process for manufacturing a population of neutrophils, such as chimeric antigen receptor-expressing (CAR-expressing) neutrophils (e.g., T cells and natural killer (NK) cells), from human pluripotent stem cells (hPSCs) using defined media and related compositions, kits, and methods of use (e.g., targeted cancer immunotherapy). Stage-specific processes for generating neutrophils and chimeric antigen receptor (CAR) neutrophils from human pluripotent stem cells (hPSCs) using chemically defined, feeder-free platforms and stage-specific morphogens; cell lines; pharmaceutical compositions; a method of treating cancer; and a kit are within the scopes of this disclosure.

公开(公告)号：US20230250400A1

公开(公告)日：2023-08-10

申请号：US18182137

申请日：2023-03-10

申请人： Xingxin Wang

发明人： Xingxin Wang

IPC分类号： C12N5/074 ,  C07K14/72 ,  C07K14/62

CPC分类号： C12N5/0696 ,  C07K14/721 ,  C07K14/62 ,  C12N2506/1384 ,  C12N2510/02 ,  C12N2500/32 ,  C12N2500/44 ,  C12N2501/115 ,  C12N2501/2303 ,  C12N2501/2317 ,  C12N2533/54

摘要： The present disclosure provides an in vitro method for preparation of human pluripotent stem cells (HPSCs) from human adipocyte-derived stem cells (ADSCs) without any genetic engineering techniques and without involving any exogenous gene elements, plasmid or transcription factors and the so obtained HPSCs are referred to as directly-generated human pluripotent stem cells (dgHPSCs). The present invention further provides an in vitro method for insulin production from the dgHPSCs by means of single- or co-transduction with human estrogen-related receptor gamma (ERRγ) gene by the lentivirus vector pWPI/ERRγ encoding the human ERRγ gene and/or with human insulin (INS) gene by a lentivirus vector, pWPI/INS encoding the human INS gene, where the insulin secreted by such co-transduced cells is higher than singly transduced cells. The present invention also provides an in vitro method for insulin production in a glucose-concentration responsive manner involving single transduction of the dgHPSCs with the human ERRγ gene.

公开(公告)号：US11713447B2

公开(公告)日：2023-08-01

申请号：US16322584

申请日：2017-08-04

申请人： Icahn School of Medicine at Mount Sinai

发明人： Camelia Iancu-Rubin ,  Ronald Hoffman

IPC分类号： C12N5/078 ,  A61K35/19

CPC分类号： C12N5/0644 ,  A61K35/19 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/999 ,  C12N2506/11

摘要： The invention is directed to production of megakaryocyte (MK) compositions and their the treatment of thrombocytopenia in a subject in need thereof.

公开(公告)号：US20230212513A1

公开(公告)日：2023-07-06

申请号：US18009192

申请日：2021-06-17

申请人： The Children's Medical Center Corporation

发明人： Ashlee J. Conway ,  Tolulope O. Rosanwo ,  Thomas E. Williamson ,  Trista E. North ,  George Q. Daley

IPC分类号： C12N5/078 ,  A61K31/573 ,  A61K31/727 ,  A61K35/16 ,  A61K35/545 ,  A61K38/18 ,  A61K38/20 ,  A61K38/28 ,  A61K38/40

CPC分类号： C12N5/0641 ,  A61K31/573 ,  A61K31/727 ,  A61K35/16 ,  A61K35/545 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/202 ,  A61K38/28 ,  A61K38/40 ,  C12N2500/25 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/2303 ,  C12N2501/39 ,  C12N2501/91

摘要： The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.

公开(公告)号：US20190194613A1

公开(公告)日：2019-06-27

申请号：US16328396

申请日：2017-09-01

申请人： TAKARA BIO INC.

发明人： Hiroki SAITO

IPC分类号： C12N5/079 ,  G01N33/50

CPC分类号： C12N5/0622 ,  A61P21/02 ,  A61P25/16 ,  A61P25/28 ,  C12N5/0645 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2334 ,  C12N2502/086 ,  C12N2502/1157 ,  C12N2502/13 ,  C12N2502/45 ,  C12N2506/45 ,  G01N33/5058

摘要： The purpose of the present invention is to efficiently produce microglia from pluripotent stem cells. Provided is a method for producing microglia from pluripotent stem cells, comprising the following steps: (a) a step of co-culturing a pluripotent stem cell together with a feeder cell for 7 days or longer, and obtaining a blood progenitor cell; (b) a step of co-culturing the blood progenitor cell obtained in step (a) together with a feeder cell in the presence of IL-3 and/or GM-CSF, and obtaining an embryonic monocyte; and (c) a step of, in the presence of M-CSF, co-culturing the embryonic monocyte obtained in step (b) together with an astrocyte, or culturing the embryonic monocyte using an astrocyte supernatant.

公开(公告)号：US20190192691A1

公开(公告)日：2019-06-27

申请号：US16092829

申请日：2017-04-11

申请人： Obsidian Therapeutics, Inc.

发明人： Peter Barrett ,  Michael N. Gladstone ,  Tariq A. Kassum ,  Vipin Suri ,  Dan Jun Li ,  Dexue Sun ,  Brian Dolinski

IPC分类号： A61K48/00 ,  A61K35/17 ,  A61P3/08 ,  C07K14/605 ,  C12N15/11 ,  C12N9/22 ,  C12N5/0789 ,  C07K14/195 ,  C07K14/54 ,  C12N9/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725

CPC分类号： A61K48/0066 ,  A61K35/17 ,  A61K38/00 ,  A61P3/08 ,  C07K14/00 ,  C07K14/195 ,  C07K14/5428 ,  C07K14/5443 ,  C07K14/605 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  C12N5/0647 ,  C12N9/22 ,  C12N9/93 ,  C12N15/11 ,  C12N2310/20 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2316 ,  C12N2800/80 ,  C12Y603/04016

摘要： The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.

公开(公告)号：US20180142212A1

公开(公告)日：2018-05-24

申请号：US15804555

申请日：2017-11-06

申请人： Fred Hutchinson Cancer Research Center ,  NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS

发明人： Irwin D. Bernstein ,  Anthony E. Boitano ,  Michael Cooke ,  Colleen Delaney

IPC分类号： C12N5/0789 ,  A61K35/28

CPC分类号： C12N5/0647 ,  A61K35/28 ,  A61K2035/124 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/38 ,  C12N2501/42 ,  C12N2501/60 ,  C12N2501/999

摘要： The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits.

公开(公告)号：US20170335282A1

公开(公告)日：2017-11-23

申请号：US15672432

申请日：2017-08-09

申请人： The Hospital for Sick Children

发明人： Martin Post ,  Michael Litvack

IPC分类号： C12N5/0786 ,  A61K35/15 ,  C12N5/0735

CPC分类号： C12N5/0645 ,  A61K35/15 ,  C12N5/0606 ,  C12N2500/90 ,  C12N2500/92 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/33 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45

摘要： Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.